Progyny, Inc. $PGNY Shares Sold by Northern Trust Corp

Northern Trust Corp lessened its stake in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 8.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 841,281 shares of the company's stock after selling 75,258 shares during the quarter. Northern Trust Corp owned 0.98% of Progyny worth $18,794,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Brooklyn Investment Group lifted its stake in shares of Progyny by 5,216.4% during the first quarter. Brooklyn Investment Group now owns 3,243 shares of the company's stock worth $72,000 after purchasing an additional 3,182 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Progyny by 233.9% during the first quarter. GAMMA Investing LLC now owns 5,379 shares of the company's stock worth $120,000 after acquiring an additional 3,768 shares during the last quarter. Sei Investments Co. purchased a new stake in shares of Progyny during the first quarter worth about $228,000. Cresset Asset Management LLC purchased a new stake in shares of Progyny during the first quarter worth about $233,000. Finally, XTX Topco Ltd purchased a new stake in shares of Progyny during the first quarter worth about $241,000. Institutional investors and hedge funds own 94.93% of the company's stock.

Insider Activity at Progyny

In related news, Director Cheryl Scott sold 2,675 shares of the business's stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $22.07, for a total transaction of $59,037.25. Following the completion of the transaction, the director owned 14,112 shares in the company, valued at $311,451.84. The trade was a 15.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Kevin K. Gordon sold 2,500 shares of the business's stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $22.04, for a total value of $55,100.00. Following the transaction, the director owned 12,501 shares of the company's stock, valued at $275,522.04. This represents a 16.67% decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,570 shares of company stock worth $238,348 in the last 90 days. 9.40% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on PGNY. Raymond James Financial set a $28.00 target price on Progyny in a research report on Friday, August 8th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $28.00 target price (up from $26.00) on shares of Progyny in a research report on Friday, August 8th. Leerink Partners raised Progyny from a "market perform" rating to an "outperform" rating and set a $28.00 target price on the stock in a research report on Tuesday, July 8th. Truist Financial lifted their target price on Progyny from $24.00 to $27.00 and gave the stock a "hold" rating in a research report on Thursday, July 17th. Finally, JPMorgan Chase & Co. lifted their target price on Progyny from $23.00 to $25.00 and gave the stock a "neutral" rating in a research report on Tuesday, August 26th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, Progyny has a consensus rating of "Moderate Buy" and a consensus target price of $25.30.

Progyny Trading Down 4.3%

Progyny stock traded down $1.01 during mid-day trading on Friday, reaching $22.55. The company's stock had a trading volume of 978,886 shares, compared to its average volume of 1,029,759. The firm has a market cap of $1.94 billion, a price-to-earnings ratio of 38.22, a PEG ratio of 1.84 and a beta of 1.33. The business has a 50 day moving average price of $22.94 and a 200-day moving average price of $22.23. Progyny, Inc. has a twelve month low of $13.39 and a twelve month high of $26.76.

Progyny (NASDAQ:PGNY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.42 by ($0.23). Progyny had a net margin of 4.28% and a return on equity of 10.69%. The company had revenue of $332.87 million for the quarter, compared to analyst estimates of $315.70 million. During the same quarter in the prior year, the firm earned $0.17 EPS. The company's revenue for the quarter was up 9.5% compared to the same quarter last year. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. On average, equities analysts expect that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.